English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 31 July 2015, 13:00 JST
Share:
    

Source: Eisai
Continuation of "Policy for Protection of The Company's Corporate Value and Common Interests of Shareholders (Shareholder Rights Plan)"

TOKYO, July 31, 2015 - (JCN Newswire) - The Board of Directors of Eisai Co., Ltd. (Chair: Kiyochika Ota) passed a resolution for the continuation of the "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders" ("the Policy"), which was proposed by the Independent Committee of Outside Directors (Chair: Osamu Suzuki, "ICOD") at its meeting held today.

The proposal to continue the Policy was deliberated at an ICOD meeting of all seven outside directors elected at the Ordinary General Meeting of Shareholders held on June 19, 2015. The ICOD determined that it was appropriate to propose the continuation of the Policy in its present form to the Board of Directors since it incorporates the following provisions:

1. The Policy precludes arbitrary actions on the part of the management
2. The continuation, amendment, or abandonment of the Policy shall be deliberated each year
3. Shareholders' opinions concerning the Policy may be reflected through the election of directors at the Ordinary General Meeting of Shareholders

The Policy was initially adopted after being proposed by the ICOD at an Eisai Board of Directors meeting held in February 2006. After subsequent changes were made to certain policy provisions through an Eisai Board of Directors meeting in August 2011, it was determined that the Policy is to remain in effect until June 30, 2016. The continuation, amendment, or abandonment of the Policy is deliberated by the newly appointed ICOD following the Ordinary General Meeting of Shareholders each year.

Further information on the Policy is provided in the "Corporate Governance" section of the Eisai Global website (http://www.eisai.com/company/ecgpolicy20150731.pdf).

At present, Eisai has not received any specific proposals concerning the large-scale purchase of the company shares.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120



Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Thursday, 18 April 2024, 10:53 JST
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Wednesday, 17 April 2024, 16:17 JST
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
2024年4月17日 10時00分 JST
エーザイ、抗てんかん剤「フィコンパ(R)」の注射剤を新発売
Wednesday, 3 April 2024, 16:24 JST
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
Monday, 1 April 2024, 9:39 JST
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575